Molecular Partners (MOLN) Competitors

Molecular Partners (NASDAQ:MOLN) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Do analysts rate MOLN or EOLS?

Molecular Partners currently has a consensus price target of $12.00, indicating a potential upside of 199.33%. Evolus has a consensus price target of $23.75, indicating a potential upside of 149.21%. Given Molecular Partners' stronger consensus rating and higher possible upside, research analysts clearly believe Molecular Partners is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Evolus	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better valuation and earnings, MOLN or EOLS?

Evolus has higher revenue and earnings than Molecular Partners. Evolus is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	28.65	-$61.39M	-$1.92	-2.09
Evolus	$266.27M	2.31	-$50.42M	-$0.89	-10.71

Is MOLN or EOLS more profitable?

Molecular Partners has a net margin of 0.00% compared to Evolus' net margin of -20.40%. Molecular Partners' return on equity of -42.20% beat Evolus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-42.20%	-38.12%
Evolus	-20.40%	-759.04%	-20.14%

Which has more risk and volatility, MOLN or EOLS?

Molecular Partners has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Evolus has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Do institutionals and insiders believe in MOLN or EOLS?

26.6% of Molecular Partners shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by insiders. Comparatively, 5.9% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the media favor MOLN or EOLS?

In the previous week, Evolus had 2 more articles in the media than Molecular Partners. MarketBeat recorded 4 mentions for Evolus and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.94 beat Evolus' score of 0.93 indicating that Molecular Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evolus	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Molecular Partners beats Evolus on 10 of the 17 factors compared between the two stocks.